{
  "pmcid": "9857805",
  "sha256": "a1b90b62f755de01823443b22e7258eecdddaeb42489008b31a65c17ab69f9cb",
  "timestamp_utc": "2025-11-09T16:22:46.260873+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 17.160949681077245,
    "reading_ease": 15.507179305457157,
    "word_count": 415
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "A within-trial economic evaluation of the Fibrinogen Replenishment in Surgery (FIBERS) randomized clinical trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants included a subset of 495 adult patients from the FIBERS trial who underwent cardiac surgery and developed active bleeding and acquired hypofibrinogenemia requiring fibrinogen replacement."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Fibrinogen concentrate (4 g per dose) or cryoprecipitate (10 units per dose) randomized (1:1) up to 24 hours postcardiopulmonary bypass."
      },
      "Objective": {
        "score": 1,
        "evidence": "Objective: To determine cost-effectiveness of fibrinogen concentrate vs cryoprecipitate for managing active bleeding in adult patients who underwent cardiac surgery."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "Effectiveness outcomes included number of ABPs administered within 24 hours and 7 days of cardiopulmonary bypass."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "randomized (1:1)"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Participants included a subset of 495 adult patients from the FIBERS trial"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Patient level costs for 495 patients were evaluated"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Median (IQR) total 7-day ABP cost was CAD $2280 (US dollars [USD] $1697) (CAD $930 [USD $692]-CAD $4970 [USD $3701]) in the fibrinogen concentrate group and CAD $2770 (USD $1690) (IQR, CAD $1140 [USD $849]-CAD $5000 [USD $3723]) in the cryoprecipitate group."
      },
      "Harms": {
        "score": 1,
        "evidence": "ABP transfusions and adverse events were similar in both treatment groups."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 16,
    "max_score": 25
  }
}